Findings showed treatment with Rybrevant plus chemotherapy significantly reduced the risk of disease progression or death by 52% compared with chemotherapy.

Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration approved RYBREVANT (amivantamab-vmjw) in combination ...

2018年1月19日，南方医科大学萍乡医院 (萍乡市人民医院)泌尿外科在Medical Science Monitor (中科院四区 IF=2.2)期刊上在线发表题为 "GP73 promotes invasion and metastasis of bladder cancer by regulating the epithelial-mesenchymal transition through ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut ...

The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival ...

The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...

Wednesday announced the receipt of Fast Track Designation from the FDA for ATR-04, a topical treatment targeting ...

The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival ...

ArriVent BioPharma is developing a treatment for non-small cell lung cancer. Click here to read more about AVBP stock and ...

Black women in the US have a significantly higher risk of breast cancer mortality across all subtypes, with disparities ...

New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy1 Results from an interim ...

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the U.S. Food and Drug ...